B. Metzler seel. Sohn & Co. AG Has $1.38 Million Stock Holdings in Elanco Animal Health Incorporated $ELAN

B. Metzler seel. Sohn & Co. AG boosted its stake in Elanco Animal Health Incorporated (NYSE:ELAN) by 81.3% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 68,558 shares of the company’s stock after purchasing an additional 30,739 shares during the period. B. Metzler seel. Sohn & Co. AG’s holdings in Elanco Animal Health were worth $1,381,000 at the end of the most recent quarter.

A number of other hedge funds have also recently added to or reduced their stakes in ELAN. Hsbc Holdings PLC lifted its holdings in shares of Elanco Animal Health by 434.2% during the second quarter. Hsbc Holdings PLC now owns 126,334 shares of the company’s stock worth $1,801,000 after purchasing an additional 102,686 shares during the period. Norges Bank acquired a new stake in Elanco Animal Health in the second quarter valued at $12,502,000. Amalgamated Bank increased its holdings in Elanco Animal Health by 793.7% in the third quarter. Amalgamated Bank now owns 226,580 shares of the company’s stock valued at $4,563,000 after purchasing an additional 201,226 shares during the period. Independent Advisor Alliance raised its position in Elanco Animal Health by 364.5% during the 3rd quarter. Independent Advisor Alliance now owns 98,025 shares of the company’s stock worth $1,974,000 after purchasing an additional 76,920 shares during the last quarter. Finally, State of Michigan Retirement System acquired a new position in Elanco Animal Health during the 3rd quarter worth about $2,383,000. Institutional investors and hedge funds own 97.48% of the company’s stock.

Elanco Animal Health Stock Performance

Shares of Elanco Animal Health stock opened at $23.68 on Wednesday. The business has a 50-day moving average price of $24.50 and a two-hundred day moving average price of $22.14. Elanco Animal Health Incorporated has a 1-year low of $8.02 and a 1-year high of $27.72. The company has a current ratio of 2.17, a quick ratio of 1.08 and a debt-to-equity ratio of 0.60. The company has a market cap of $11.77 billion, a P/E ratio of -49.32, a PEG ratio of 3.04 and a beta of 1.83.

Elanco Animal Health (NYSE:ELAN) last announced its quarterly earnings data on Tuesday, February 24th. The company reported $0.13 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.11 by $0.02. Elanco Animal Health had a positive return on equity of 7.16% and a negative net margin of 4.92%.The company had revenue of $1.14 billion for the quarter, compared to the consensus estimate of $1.09 billion. During the same period in the previous year, the business earned $0.14 EPS. The firm’s revenue was up 12.2% compared to the same quarter last year. Elanco Animal Health has set its Q1 2026 guidance at 0.330-0.36 EPS and its FY 2026 guidance at 1.000-1.060 EPS. As a group, analysts anticipate that Elanco Animal Health Incorporated will post 0.91 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research firms have commented on ELAN. Argus upgraded Elanco Animal Health from a “hold” rating to a “buy” rating and set a $25.00 price target on the stock in a research report on Wednesday, November 19th. JPMorgan Chase & Co. raised their price objective on Elanco Animal Health from $24.00 to $28.00 and gave the stock an “overweight” rating in a research report on Thursday, February 19th. UBS Group reaffirmed a “buy” rating on shares of Elanco Animal Health in a research note on Tuesday. Weiss Ratings reiterated a “sell (d+)” rating on shares of Elanco Animal Health in a report on Monday, December 29th. Finally, Piper Sandler raised shares of Elanco Animal Health from a “neutral” rating to an “overweight” rating and increased their target price for the company from $24.00 to $30.00 in a research report on Thursday, January 22nd. One equities research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $27.67.

Insiders Place Their Bets

In related news, Director Lawrence Erik Kurzius acquired 10,000 shares of Elanco Animal Health stock in a transaction dated Friday, December 12th. The stock was bought at an average price of $21.30 per share, with a total value of $213,000.00. Following the transaction, the director directly owned 131,773 shares in the company, valued at $2,806,764.90. This represents a 8.21% increase in their position. The purchase was disclosed in a filing with the SEC, which is available at the SEC website. Also, CEO Jeffrey N. Simmons acquired 22,000 shares of the stock in a transaction dated Thursday, December 11th. The stock was bought at an average price of $21.75 per share, with a total value of $478,500.00. Following the purchase, the chief executive officer directly owned 167,000 shares in the company, valued at $3,632,250. This represents a 15.17% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders bought a total of 43,450 shares of company stock valued at $937,883 in the last ninety days. 0.89% of the stock is owned by corporate insiders.

About Elanco Animal Health

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.